AMDL readies colorectal cancer test data requested by FDA:
This article was originally published in Clinica
Executive Summary
After its failure last year to gain US 510(k) market clearance for its DR-70 colorectal cancer monitoring blood test, AMDL says it has completed the studies and compiled the data that had been requested by the agency. "AMDL will be requesting a meeting with the FDA to present the data, which we believe is compelling," said the Tustin, California firm's CEO, Gary Dreher.